Alessa Therapeutics

Alessa Therapeutics announced a presentation of positive preliminary safety and efficacy data from Enolen’s Phase 1 trial at the 2026 American Urological Association meeting.

The text describes Fast Track Designation as highlighting Enolen’s potential to address an unmet medical need for patients with low- to intermediate-risk localized prostate cancer. Alessa Therapeutics expects to provide initial findings from Enolen’s Phase 1 trial later this year.

First study to demonstrate safe and selective administration of sustained and localized delivery of enzalutamide

Alessa Therapeutics announced the formation of its Clinical Advisory Board to support the continued clinical advancement of Enolen.

Alessa Therapeutics offers career opportunities.

Alessa Therapeutics is developing a proprietary drug-delivery platform for sustained and localized release of clinically proven therapies to effectively treat early-stage prostate cancer

Alessa Therapeutics secures FDA confirmation that a single pivotal Phase 3 study with progression-free survival as the primary endpoint will support an NDA submission for Enolen. The company plans to initiate the trial in mid-2027, following the regulatory feedback.

Jul 2026Alessa Therapeutics |News article

Alessa Therapeutics presents Phase 1 study results for **Enolen**, its localized drug delivery treatment for early-stage urological conditions, at the **American Urological Association (AUA) Annual Meeting**. The presentation earns the **‘Best Poster’ award**, recognizing its clinical progress. Alessa specializes in novel drug delivery technologies targeting localized therapies in urology.

May 2026EIN PresswireNews article

Alessa Therapeutics reports the first Phase 1 trial showing **Enolen**—a sustained, localized delivery system for enzalutamide—demonstrates **safe administration** and **selective efficacy** in early testing. The trial marks a potential advancement in targeted treatment for conditions responsive to enzalutamide, a drug used in prostate cancer therapy. Researchers highlight the system’s ability to maintain drug levels at the treatment site while minimizing systemic exposure.

Mar 2026BioSpaceNews article

Alessa Therapeutics secures FDA Fast Track designation for **Enolen**, a novel treatment targeting **low- to intermediate-risk localized prostate cancer**. The company plans to share initial Phase 1 trial results later in 2026, aiming to address unmet needs in this patient population. Enolen represents a first-in-class approach for localized prostate cancer therapy.

Jan 2026Alessa Therapeutics |News article